Company profile
Defence Therapeutics Inc.
OTC: DTCFF · Healthcare · Biotechnology
Canadian filerHQ Vancouver, QCReports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH 30DQ —GM —SS 53
v0.1 · 35/100 weight · pillars only
↑ workforce scale, Altman-Z · ↓ return on assets, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$2.9M
Employees
1,300
as of 2026-08-21
Market cap
$26.1M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2025
Net income-$2.9M-4.0M CAD2025
Operating income-$2.1M-3.0M CAD2025
Total assets$1.2M1.7M CAD2025
Liabilities$2.1M2.9M CAD2025
Equity-$733.0k-1.0M CAD2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Defence Therapeutics Inc.’s revenue?
Defence Therapeutics Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
High Sierra Technologies, Inc.——BeyondSpring Inc.34DSona Nanotech Inc.——Resverlogix Corp.——EOM Pharmaceuticals Holdings, Inc.——Barinthus Biotherapeutics plc39DKey facts
CEOAmie Phinney
SectorHealthcare
IndustryBiotechnology
HeadquartersVancouver, QC
ExchangeOTC: DTCFF
Employees1,300
IPO date2021-05-18
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.